RIDDLE&CODE
1.4.2022 10:17:06 CEST | Business Wire | Press release
As of April 1, 2022 , Kai Siefert will take over the managing director position of the blockchain start-up RIDDLE&CODE Energy Solutions GmbH, a joint venture between Wien Energie GmbH, Austria's largest regional energy service provider, and blockchain scale-up RIDDLE&CODE GmbH, also based in Vienna.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005045/en/
Kai Siefert has 16 years of professional experience in the energy industry. In his previous position as IT strategist at Wien Energie GmbH, he led a team of software developers and electrical engineers from both joint venture partners to develop blockchain-based digital services and technical solutions for the renewable sector and its distributed energy sources. As a result of this work, the energy tokenisation platform "MyPower" was launched last summer, forming the core product of the young company. Wien Energie GmbH already uses this technology as part of its citizen solar power plant products, where the latest release includes a dynamic incentivisation and remuneration feature.
“Over the past four years, the team has built a digital framework for everyone to participate in decentralised energy markets,” says Siefert. “By using this framework, energy entrepreneurs are able to overcome even the toughest problems, such as asset aggregation and disaggregation, peer-to-peer energy marketing or certificate management. Based on our state-of-the-art tokenisation technology and digital wallets, we provide them with secure, transparent and highly scalable access to value chains of the green economy." As part of his new role, Siefert will focus on the internationalisation of the company and further development of the MyPower platform.
"We have proven the technical and commercial viability of energy tokenization in several "real-market projects" in Vienna. And there is great interest in the solution beyond the Austrian borders. As an immediate success of the whole RIDDLE&CODE Energy Solutions team, I am happy to announce the cooperation with the municipality of Stanz, the Austrian pioneer community of the EU-funded Smart Rural project, which was sealed earlier this week.", says Kai Siefert.
"Kai has done a great job with MyPower, driving strong growth, partnerships, and fantastic product innovation. His track record in the industry speaks for itself as well as his empathy for the challenges enterprises overcome while adopting blockchain technology," said Alexander Koppel, CEO at RIDDLE&CODE GmbH. "We are thrilled to have him as a managing director as we accelerate the next stage of growth."
About RIDDLE&CODE Energy Solutions GmbH
RIDDLE&CODE Energy Solutions GmbH provides blockchain-powered infrastructure that enables resilient, decentralised and fully decarbonized energy markets. With the development of the MyPower platform, the company has demonstrated an effective way for energy players into the machine economy. By tokenizing energy, machines and data, RIDDLE&CODE Energy Solutions GmbH significantly increases the liquidity of distributed assets making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
